BIO-key International (NASDAQ:BKYI) Announces Earnings Results

BIO-key International (NASDAQ:BKYI) issued its quarterly earnings data on Friday. The technology company reported ($4.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($3.66), Zacks reports. The firm had revenue of $1.48 million during the quarter, compared to analyst estimates of $2.40 million. BIO-key International had a negative net margin of 50.01% and a negative return on equity of 67.31%.

Here are the key takeaways from BIO-key International’s conference call:

• Software growth lifted margins: Q3 license-fee revenue rose 39% year over year and reached 86% of total revenue, helping gross margin improve to 90% from 77% and reducing the operating loss 8%. Total revenue nevertheless fell 4%, largely because hardware sales declined.
• International regulated-sector wins expanded the pipeline: BIO-key highlighted new government and financial-services customers, including the Central Bank of Jordan, and said it has added eight Middle East customers in roughly seven months. Management described larger opportunities ahead, but timing and collections remain dependent on customer and partner deployments.
• New U.S. opportunities and product initiatives: A casino resort signed a prepaid, three-year PortalGuard agreement, and BIO-key said its FIDO-certified Passkey:YOU product is nearing launch, with agentic-AI authentication as a potential use case. Management sees partner-led sales and additional verticals as growth opportunities, though adoption is not yet established.
• Balance sheet strengthened: The company retired its remaining note debt, ended the quarter with $2.2 million in cash and $3.1 million of working capital, and said it does not currently expect to need additional capital. Management is targeting profitability as it approaches Q1 2027.
• Reported loss per share was sharply affected by a financing-related accounting item: A non-cash $4.5 million deemed dividend tied to an August warrant inducement brought Q3 net loss available to common stockholders to $5.9 million, or $4 per share, despite improvement in the operating loss. Hardware revenue also fell to $12,000 from $364,000 a year earlier, with a large customer order delayed into smaller shipments.

BIO-key International Stock Performance

Shares of BIO-key International stock traded down $0.46 during trading on Friday, reaching $2.12. The company had a trading volume of 215,583 shares, compared to its average volume of 1,709,838. The company has a market cap of $4.32 million, a price-to-earnings ratio of -0.52 and a beta of 0.52. The firm’s fifty day moving average is $2.47 and its 200-day moving average is $4.41. BIO-key International has a fifty-two week low of $1.55 and a fifty-two week high of $10.70.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Zacks Research raised shares of BIO-key International to a “hold” rating in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BIO-key International in a report on Thursday, October 15th. Finally, Wall Street Zen raised shares of BIO-key International to a “hold” rating in a research note on Saturday, October 24th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BIO-key International currently has an average rating of “Reduce”.

About BIO-key International

BIO-key International, Inc. (NASDAQ: BKYI) develops biometric authentication and identity and access management solutions. The company helps organizations secure access to applications, networks, devices and data through fingerprint recognition and other authentication methods designed to reduce reliance on passwords. Its product portfolio includes PortalGuard, an identity and access management platform that supports single sign-on, multifactor authentication, self-service password management and access control.